LEXINGTON, Mass. / Jul 26, 2023 / Business Wire / Immuno-oncology leader, Agenus (Nasdaq: AGEN), today announced the Company will release its second quarter 2023 financial results via press release before the market opens on Tuesday, August 8, 2023.
In addition, Dr. Garo Armen, Chairman and CEO of Agenus, will participate in the following upcoming investor conferences:
A replay of the fireside chat from the BTIG conference can be accessed on the company’s website at https://investor.agenusbio.com/events-and-presentations following the event.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The Company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics), and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or follow us on LinkedIn and Twitter @agenus_bio.
| Last Trade: | US$4.32 |
| Daily Change: | -0.24 -5.26 |
| Daily Volume: | 767,916 |
| Market Cap: | US$146.920M |
November 19, 2025 October 17, 2025 October 16, 2025 September 09, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
